TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist

SOUTH SAN FRANCISCO, April 29, 2026 – TRex Bio, Inc. (“TRexBio”), a clinical-stage biotechnology company discovering and developing immunoregulatory medicines based on tissue Treg biology, today announced that the first patient has been dosed in the Phase 1b portion of its ongoing clinical trial of TRB-061, a novel TNFR2 agonist in development for the treatment of […] The post TRexBio Doses First Patient with Moderate-to-Severe Atopic Dermatitis in Phase 1b Clinical Trial of TRB-061, a TNFR2 Agonist appeared first on TrexBio .